Navigation Links
Leading Oncologists from Across the Country Hold Emergency Meeting on New Government Reimbursement Policy for Medicare Patients with Cancer

Oncologists Point to Science, Quality Outcomes, Safety Concerns and Interference with Doctors' Expertise as Reasons to Revisit NCD

CHICAGO, Oct. 24 /PRNewswire-USNewswire/ -- Leading oncologists from across the country gathered in Chicago today to discuss concerns and reach consensus over the new National Coverage Decision (NCD) for the use of Erythropoiesis Stimulating Agents (ESAs) in cancer treatments for Medicare patients. The meeting, which brought together approximately 50 of the nation's leading oncologists, was chaired by Dr. Peter Ellis, Medical Director of the University of Pittsburgh's Medical Center (UPMC) Cancer Centers.

ESAs are used to boost patients' red blood cell counts when undergoing chemotherapy, which allows them to better cope with the treatment regimen. The NCD is putting restrictions on Medicare reimbursement for hemoglobin levels at 10g/dL. Since the new NCD guidelines were first introduced in late July by the Centers for Medicare and Medicaid Services (CMS), oncologists and patients from across the country have come forward expressing concern over what many regard as interference by the government on cancer doctors' medical decisions for their patients.

The oncologists created a statement today based on remarks from leading health policy experts and a satellite briefing from Washington, DC featuring physicians who had participated in meetings at the Centers for Medicare and Medicaid Services (CMS) where they discussed revisiting the NCD allowing doctors to administer ESAs before a patient's hemoglobin level drops below 10. Since Medicare will not reimburse at any amount above a hemoglobin level of 10, patients could be subjected to blood transfusions which many oncologists regard as unnecessary and expose the patient to added health risks.

The final statement, which is being sent to policymakers in Washington and widely distributed among their peers and patient groups across the country, reads as follows:

We support an evidence-based uniform coverage policy for anemia management of Medicare patients undergoing chemotherapy treatment through the development of a National Coverage Determination (NCD), and share CMS' concern regarding the safety of Erythropoiesis Stimulating Agents (ESAs) when administered to patients who are above the hemoglobin (hgb) level of 12g/dL.

Over 40 scientific studies support the safe and effective use of ESAs in chemotherapy induced anemia when administered up to hgb 12g/dL. There is no evidence of tumor progression or increased mortality in the use of ESAs in accordance with the FDA label up to hgb 12g/dl.

The current NCD poses significant health risks to Medicare cancer patients. As no published research indicates that stopping ESAs at hgb of 10g/dL will be safe or effective, this policy exposes cancer patients to needless blood transfusions with associated risks.

The NCD, by limiting our ability to use supportive care drugs appropriately, hinders oncologists' ability to provide life saving or life prolonging treatments and will impose different, less effective cancer treatment regimens.

The NCD does not acknowledge the valuable improvements in quality of life which numerous studies have documented to be derived from appropriate ESA usage.

The NCD forces physicians and patients to choose between the standard of care versus what Medicare's coverage policy will reimburse thus creating a two-tiered system of care where Medicare patients receive substandard care.

We urge CMS to:

1- Acknowledge as the clinical standard of care for determining

medical necessity in the use of ESAs the October 22, 2007

evidence-based guidelines for patient treatment established by the

American Society of Clinical Oncology (ASCO) and the American

Society of Hematology (ASH);

2- Reconsider the ESA NCD and alter the final coverage determination to

reflect the ASCO-ASH guidelines.

SOURCE US Oncology
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Misleading anti-malarial drug
3. Misleading Advertisements for Prescription Drugs
4. The Effects Of Smoking Misleading
5. Antidepressant Medication Leading To Suicidal Thoughts
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Historic trial for tuberculosis launched together by leading drug companies
8. Alcohol And Drug Abuse (Cannabis) Leading Causes For Road Traffic Accidents
9. Down’s Syndrome Is The Leading Birth Defect In the U
10. Exposure to Grating, Noise, Music Can Cause Tumors Leading To Deafness
11. Bottleneck: High on Spirits Can Cause A Dispirited Liver, Leading To Cirrhosis!
Post Your Comments:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: